Avelumab Program Rollover Study

Inclusion Criteria

• Participants under enrollment and treatment in an avelumab clinical study under the sponsorship of EMD Serono Research & Development Institute, Inc. / Merck KGaA, Darmstadt, Germany

  • Merck Serono Co., Ltd (Japan)

• Participants currently enrolled in an avelumab parent study and are on active treatment with avelumab or in long-term survival follow-up after treatment

• Participants on active treatment must agree to continue to use highly effective contraception (that is, methods with a failure rate of less than 1% per year) for both male and female participants if the risk of conception exists

• Other protocol defined inclusion criteria could apply.

Exclusion Criteria

• Participants who are pregnant or breastfeeding
• Participants still on active treatment: Known hypersensitivity to any of the study intervention ingredients
• Participant has been enrolled in the comparator arm of avelumab parent study
• Participant has been withdrawn from avelumab parent study for any reason
• Any other reason that, in the opinion of the Investigator, precludes the participant from participating in the study
• Other protocol defined exclusion criteria could apply.